Clinical trial
An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Advanced Solid Tumors
NCT03010982 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Advanced Solid Tumors
- Lead sponsor
- Epizyme, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 20, 2018
- Completion date
- January 8, 2019
- Enrollment
- 3 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumors, diffuse large b cell lymphoma, follicular lymphoma, mantle-cell lymphoma, marginal zone lymphoma, primary mediastinal lymphoma